Vidagliptin + Metformin Tablets

Project Image
Thumb Image

Therapeutic Indication

Type 2 diabetes mellitus (glycemic control)
Combination therapy when diet and exercise alone are insufficient
Dual mechanism: incretin enhancement + reduced hepatic glucose output
Cardiovascular and metabolic risk reduction (adjunct)
+91 85919 78885

Vidagliptin + Metformin

Tablet

Vidagliptin and Metformin Hydrochloride Tablets combine a DPP-4 inhibitor and a biguanide. Vidagliptin enhances incretin activity, increasing insulin secretion and reducing glucagon levels. Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they provide effective glycemic control in type 2 diabetes mellitus.

Speciality Antidiabetic | Combination Therapy
Tags Type 2 Diabetes | DPP-4 Inhibitor | Biguanide | Glycemic Control
Strength
  • Vidagliptin 50 mg
  • Metformin 500 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Vidagliptin inhibits DPP-4 enzyme, prolonging incretin activity, which increases insulin release and decreases glucagon secretion. Metformin reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and enhances peripheral glucose uptake. The combination provides complementary mechanisms for improved glycemic control.

Pharmacokinetics

  • Absorption: Vidagliptin — rapid oral absorption; Metformin — absorption mainly in small intestine
  • Distribution: Both widely distributed; Metformin not protein bound
  • Metabolism: Vidagliptin — hepatic metabolism; Metformin — not metabolized
  • Elimination: Vidagliptin — renal excretion; Metformin — excreted unchanged in urine
  • Half-life: Vidagliptin ≈ 3 hours; Metformin ≈ 6 hours

Side Effects

  • Nausea
  • Diarrhea
  • Headache
  • Upper respiratory tract infection
  • Rare: lactic acidosis, pancreatitis

Contraindication

  • Hypersensitivity to Vidagliptin, Metformin, or excipients
  • Renal impairment (eGFR < 30 mL/min/1.73m²)
  • Hepatic impairment
  • Alcoholism
  • Conditions predisposing to lactic acidosis

Interaction

  • Alcohol — increases risk of lactic acidosis with Metformin
  • Rifampicin — may reduce efficacy of Vidagliptin
  • Cationic drugs (e.g., cimetidine) — compete for renal tubular secretion with Metformin
  • Other antidiabetic agents — additive hypoglycemic effect

Warning and Precautions

  • Monitor renal function before and during therapy
  • Discontinue if lactic acidosis is suspected
  • Use cautiously in elderly patients
  • Monitor liver enzymes periodically with Vidagliptin
  • Advise patients to avoid excessive alcohol intake